WHO Solidarity Trial: Repurposed Antiviral Drugs for Covid-19

Name of the Trial
WHO Solidarity Trial
Title of the Trial
Repurposed Antiviral Drugs for Covid-19
Open-label, randomized controlled trial
Year of Publication
To assess the safety and efficacy of four drugs: remdesivir, hydroxychloroquine, lopinavir, interferon in treating patients hospitalized with coronavirus disease 2019 (COVID-19)
Number of Patients (N)
Inclusion Criteria
-Age ≥18 years
-Hospitalization with COVID-19
-Not known to have received any trial drug
-Were not expected to be transferred elsewhere within 72 hours
-No contraindications
Exclusion criteria
-hypersensitivity to tocilizumab
-Active bacterial infection
-Severely Neutropenic, thrombocytopenic
Duration of Follow up
28 days
Comparison groups
Remdesivir (n = 2,750), Hydroxychloroquine (n = 954), lopinavir without interferon (n = 1,411), interferon with or without lopinavir (n = 2,063), no trial drug (n = 4,088)
Primary Outcomes
In-hospital mortality

Remdesivir vs. control: 12.5% vs. 12.7%, p = 0.5
Hydroxychloroquine vs. control: 10.2% vs. 8.9%, p = 0.23
Lopinavir vs. control: 9.7% vs. 10.3%, p = 0.97
Interferon vs. control: 12.9% vs. 11%, p = 0.11
Key Secondary Outcomes
No drug definitely reduced mortality, overall or in any subgroup, or reduced initiation of ventilation or hospitalization duration.
Remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had little or no effect on hospitalized patients with Covid-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay.
Citation, article link
WHO Solidarity Trial Consortium. Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. NEJM, 2020.